Showing results (171-180 of 302) with videos related to
Sort By:
Pageof 31
Nature Medicine|August 24, 2005
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphomaSattva S Neelapu, Larry W Kwak, Carol B Kobrin, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.Leukemia Research|September 15, 2014
Clinical significance of microcytosis in patients with primary myelofibrosisPaolo Strati, Naveen Pemmaraju, Zeev Estrov, et al.Haematologica|May 27, 2014
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletionPaolo Strati, Michael J Keating, Susan M O'Brien, et al.Nature|January 28, 2014
Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell developmentXindong Liu, Xin Chen, Bo Zhong, et al.Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.Blood Advances|October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaFrederick L Locke, John M Rossi, Sattva S Neelapu, et al.British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.Blood Advances|March 3, 2025
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022Ajay K Gopal, Philippe Armand, Sattva S Neelapu, et al.Pageof 31